Related references
Note: Only part of the references are listed.Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study
Santtu Heinonen et al.
LANCET INFECTIOUS DISEASES (2011)
Vaccination, squalene and anti-squalene antibodies: Facts or fiction?
Giuseppe Lippi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2010)
The virosomal adjuvanted influenza vaccine
Selma Calcagnile et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk
Paolo Durando et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines
Vanessa Vankerckhoven et al.
EXPERT OPINION ON DRUG DELIVERY (2010)
Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection
Susanna Esposito et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Enhanced Memory Responses to Seasonal H1N1 Influenza Vaccination of the Skin with the Use of Vaccine-Coated Microneedles
Yeu-Chun Kim et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Dissolving polymer microneedle patches for influenza vaccination
Sean P. Sullivan et al.
NATURE MEDICINE (2010)
Changes in Human Langerhans Cells Following Intradermal Injection of Influenza Virus-Like Particle Vaccines
Marc Pearton et al.
PLOS ONE (2010)
Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence
Timo Vesikari et al.
PEDIATRICS (2010)
Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine
Chin-Fen Yang et al.
VACCINE (2010)
New emerging technologies and the intradermal route: the novel way to immunize against influenza
Ann R. Falsey
VACCINE (2010)
A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months
Susanna Esposito et al.
VACCINE (2010)
Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells
Althaf I. Hussain et al.
VACCINE (2010)
Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis
Steven Black et al.
VACCINE (2010)
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial
Francois Roman et al.
VACCINE (2010)
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin
Larry R. Smith et al.
VACCINE (2010)
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
Alfonso Carmona et al.
VACCINE (2010)
Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy
Susanna Esposito et al.
VIROLOGY JOURNAL (2010)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
Claire S. Waddington et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Trends in development of the influenza vaccine with broader cross-protection
A. Stropkovska et al.
ACTA VIROLOGICA (2010)
The Burden of Influenza in Children: Time for Prevention
Kathryn M. Edwards
CLINICAL INFECTIOUS DISEASES (2009)
Virologically Confirmed Population-Based Burden of Hospitalization Caused by Influenza A and B among Children in Hong Kong
Susan S. Chiu et al.
CLINICAL INFECTIOUS DISEASES (2009)
The rational use of influenza vaccines in healthy children and children with underlying conditions
Susanna Esposito et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2009)
Continuous cell lines as a production system for influenza vaccines
Yvonne Genzel et al.
EXPERT REVIEW OF VACCINES (2009)
Benefits of Increasing the Dose of Influenza Vaccine in Residents of Long-Term Care Facilities: A Randomized Placebo-Controlled Trial
Herman J. M. Cools et al.
JOURNAL OF MEDICAL VIROLOGY (2009)
Monoclonal Antibodies against the Fusion Peptide of Hemagglutinin Protect Mice from Lethal Influenza A Virus H5N1 Infection
Nayana Prabhu et al.
JOURNAL OF VIROLOGY (2009)
Efficacy of Injectable Trivalent Virosomal-Adjuvanted Inactivated Influenza Vaccine in Preventing Acute Otitis Media in Children With Recurrent Complicated or Noncomplicated Acute Otitis Media
Paola Marchisio et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Timo Vesikari et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: A randomized controlled trial
Susan S. Chiu et al.
VACCINE (2009)
Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus
Gian Vincenzo Zuccotti et al.
VACCINE (2009)
Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older
Pierre J. T. De Villiers et al.
VACCINE (2009)
Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials
Janelle Rhorer et al.
VACCINE (2009)
Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among US military service members
Angelia A. Eick et al.
VACCINE (2009)
Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection
Filippo Ansaldi et al.
VACCINE (2009)
MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination
T. Vesikari et al.
VACCINE (2009)
Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults
Tino F. Schwarz et al.
VACCINE (2009)
Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials
Matthew Shun-Shin et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Improving seasonal and pandemic influenza vaccines
Melanie Saville et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2008)
Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy
Alessandra Vigano et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults
David I. Bernstein et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Effectiveness of maternal influenza immunization in mothers and infants
K. Zaman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age
Timo Vesikari et al.
PEDIATRICS (2008)
Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy
Susanna Esposito et al.
VACCINE (2008)
Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination
Tetsu Sugimura et al.
VACCINE (2008)
MF59 is a safe and potent vaccine adjuvant for flu Vaccines in humans: What did we learn during its development?
D. T. O'Hagan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects
Robert B. Couch et al.
VACCINE (2007)
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Derek T. O'Hagan
EXPERT REVIEW OF VACCINES (2007)
Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma
Gianvincenzo Zuccotti et al.
VACCINE (2007)
Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza
Susan E. Coffin et al.
PEDIATRICS (2007)
Live attenuated versus inactivated influenza vaccine in infants and young children
Robert B. Belshe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine
Alenka M. Zeman et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2007)
Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
Stephen Mark Tompkins et al.
EMERGING INFECTIOUS DISEASES (2007)
Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection
Krow Ampofo et al.
PEDIATRICS (2006)
Inflexal® V -: The influenza vaccine with the lowest ovalbumin content
O. Kuersteiner et al.
VACCINE (2006)
Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years:: A prospective cohort study
L. Salleras et al.
VACCINE (2006)
Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections
Shai Ashkenazi et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons
Wendy A. Keitel et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy
E Tanzi et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Severe pediatric influenza in California, 2003-2005: Implications for immunization recommendations
JK Louie et al.
PEDIATRICS (2006)
Influenza-associated deaths among children in the United States, 2003-2004
N Bhat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Adverse events reported following live, cold-adapted, intranasal influenza vaccine
HS Izurieta et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004
DK Mitchell et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2005)
Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children
G Kanra et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland
M Mutsch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children
MK Iwane et al.
PEDIATRICS (2004)
Vaccine adjuvants: Current state and future trends
N Petrovsky et al.
IMMUNOLOGY AND CELL BIOLOGY (2004)
Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households
S Esposito et al.
VACCINE (2003)
Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children
P Marchisio et al.
CLINICAL INFECTIOUS DISEASES (2002)
Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes
A Arkema et al.
VACCINE (2000)
Influenza and the rates of hospitalization for respiratory disease among infants and young children.
HS Izurieta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
The impact of influenza epidemics on hospitalizations
L Simonsen et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
